Mateon Therapeutics, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents for the treatment of cancer in the United States. Its principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating neuroendocrine tumors. The company also develops OXi4503 that is in Phase I/II clinical trial stage for treating patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.